Meryl Zausner

Meryl Zausner is an award-winning, C-suite executive with over 35 years of management experience across the pharmaceutical and consumer products industries. Known for her business savvy, strategic insights and financial acumen, Meryl was instrumental in creating the blueprint for the successful Novartis Oncology Business Unit and engineering the launch of the first Novartis shared services organization. A recognized developer of diverse talent, The Healthcare Businesswomen Association honored Meryl with its prestigious Woman of Year Award. Currently, Meryl is sought out by leaders seeking counsel on strategy, finance and people, while serving on nonprofit boards.

For much of her corporate career, Meryl worked at Novartis AG, the Swiss pharmaceuticals company, in roles of increasing responsibility across diversified businesses. Acknowledging her strong leadership and broad achievements, Novartis selected Meryl to train and serve as a certified Executive Coach to senior executives, a position she held from May 2015 until her retirement at the end of June 2017.

From April 2012 through 2014, Meryl was Chief Financial and Administrative Officer of Novartis Pharmaceuticals Corporation in the US, and a member of the Pharmaceutical Executive Committee and Global Finance Leadership Team. While in this role, Meryl also resumed responsibility as Chief Financial Officer and Executive Vice President of Novartis Corporation in the US, a position she held from 2008 to early 2012. As the US Corporate CFO, Meryl oversaw the creation of the cross divisional North American Finance Service Center, which has become a global best practice. She also led Investor Relations, Controlling, Treasury, Cash Management, Tax, Finance Talent Development, and Risk Management across the US, as well as the financial management of the Novartis benefit plans.

From 2000 to 2008, Meryl was Vice President and CFO of Novartis Global Oncology and a member of the Oncology leadership team, playing a key role in growing the internal start-up to double-digit growth year over year, and launching several groundbreaking therapies, including Gleevec/Glivec. In addition, Meryl chaired the Novartis Pharmaceuticals Global Diversity Council, of which she was a founding member. She was also a founding member of the U.S. EWIN (Empowering Women to Impact Novartis) Initiative. In 2007, she was named Healthcare Businesswomen Association’s (HBA) Woman of the Year.

From 1988 until 2000, Meryl held Finance leadership roles in the Novartis Pharmaceutical and Consumer businesses. Earlier, Meryl worked at Colgate Palmolive and in public accounting. She has a BS in Economics and Accounting from the University at Albany and her CPA.

Meryl is a Board member and Chair of the Audit Committee of Neon Therapeutics Inc., participated in their IPO, Board and Audit Committee member of Seres Therapeutics Inc, and Board and past audit chair of the Multiple Myeloma Research Foundation. Former Board positions include: HBA Advisory Board, Deidre’s House, PhRMA Audit and Finance Subcommittee member, and the T.J. Martell Foundation. PharmaVoice magazine recognized Meryl among its Most Inspiring, and she received Gilda Club’s Red Door Honoree. Meryl resides with her husband in Naples, Florida and Long Branch, New Jersey.